MDT - Medtronic plc

NYSE - Nasdaq Real Time Price. Currency in USD
97.185
+0.305 (+0.31%)
As of 9:31AM EDT. Market open.
Stock chart is not supported by your current browser
Previous Close96.880
Open95.810
Bid95.150 x 800
Ask97.350 x 2200
Day's Range97.000 - 97.350
52 Week Range76.410 - 97.380
Volume91,209
Avg. Volume4,613,798
Market Cap131.249B
Beta0.70
PE Ratio (TTM)41.91
EPS (TTM)2.319
Earnings DateNov 20, 2018
Forward Dividend & Yield2.00 (2.06%)
Ex-Dividend Date2018-09-27
1y Target Est102.45
Trade prices are not sourced from all markets
  • Final Trade: WYNN, BOX & more
    CNBC Videos12 days ago

    Final Trade: WYNN, BOX & more

    The "Fast Money" traders share their final trades of the day, including Wynn Resorts, Box, Home Depot and Medtronic.

  • Want to make six figures? Minneapolis is a good place to be (slideshows)
    American City Business Journals18 hours ago

    Want to make six figures? Minneapolis is a good place to be (slideshows)

    The companies in Minneapolis with the most openings for six-figure-salary jobs are the University of Minnesota, Boston Scientific Corp., Fairview Health Services, UnitedHealth Group and Allina Health, according to Ladders.

  • Medtronic Announces Clinical Study of Transcatheter Aortic Valve Replacement in Aortic Stenosis Patients with Bicuspid Valves
    GlobeNewswire23 hours ago

    Medtronic Announces Clinical Study of Transcatheter Aortic Valve Replacement in Aortic Stenosis Patients with Bicuspid Valves

    September 18, 2018 - Medtronic plc (MDT) today announced that the U.S. Food and Drug Administration (FDA) has approved an investigational device exemption (IDE) to initiate a single-arm study to evaluate the CoreValve Evolut(TM)TAVR system in patients with bicuspid aortic valves who are at low risk of surgical mortality. Medtronic separately received FDA approval for revised commercial labeling for the CoreValve Evolut TAVR system that removed a precaution for the treatment of bicuspid severe aortic stenosis patients deemed at intermediate or greater risk for surgical aortic valve replacement.

  • Houston startup accelerator hires med device industry veteran
    American City Business Journalsyesterday

    Houston startup accelerator hires med device industry veteran

    The Fannin Innovation Studio was founded in 2005 and invests in the early-stage medical technology and life sciences companies.

  • Medtronic Joins Catalyst CEO Champions For Change and Pledges to Accelerate Women Into Management and Board Seats
    GlobeNewswire2 days ago

    Medtronic Joins Catalyst CEO Champions For Change and Pledges to Accelerate Women Into Management and Board Seats

    September 17, 2018 - Medtronic plc (MDT) today announced it has joined the Catalyst CEO Champions For Change. This transformational diversity and inclusion initiative was launched by Catalyst - a global thought leader and partner in accelerating the progress of women at work for over 50 years. Accelerate progress in the representation of women, including women of color, in executive/senior level positions over five years.

  • A Look at Boston Scientific’s Valuation Multiples in September
    Market Realist2 days ago

    A Look at Boston Scientific’s Valuation Multiples in September

    On September 14, Boston Scientific (BSX) was trading at a forward PE (price-to-earnings) ratio of 24.4x, compared to the industry’s average PE ratio of 22.4x. Boston Scientific’s forward EV-to-EBITDA multiple is 19.1x, which is higher than the industry average of 16.7x. On September 14, Boston Scientific’s peers Abbott Laboratories (ABT), Edwards Lifesciences (EW), and Medtronic (MDT) had forward PE multiples of 21.7x, 28.4x, and 18.3x, respectively.

  • Boston Scientific Stock in the Week Ended September 14
    Market Realist2 days ago

    Boston Scientific Stock in the Week Ended September 14

    BSX stock is trading ~53.0% higher than its 52-week low of $24.54 reported on December 6, 2017. Over the last week, BSX stock has risen ~4.5%. BSX stock has risen ~11.6% over the last month. Year-to-date, BSX stock has reported stellar gains of ~52.0%.

  • 5 Medical Device Stocks With Impressive Staying Power
    InvestorPlace6 days ago

    5 Medical Device Stocks With Impressive Staying Power

    Easily the biggest trend in investing has to be healthcare stocks. From rising and aging populations in the developed world to new middle-class consumers gaining access to healthcare for the first time in emerging markets, healthcare demand is only getting bigger by the day. All in all, the combination of the two factors makes the medical device stocks some of best plays in all of healthcare.

  • Medtronic Recognized for Its Sustainability Leadership
    GlobeNewswire6 days ago

    Medtronic Recognized for Its Sustainability Leadership

    September 13, 2018 - Medtronic plc (MDT) was recognized today as one of the world`s leading companies for sustainability with its ranking on the Dow Jones Sustainability North America Index (DJSI North America) for the eleventh consecutive year. DJSI North America analyzes companies on a variety of sustainability criteria, including economic performance, environmental stewardship, social responsibility, and corporate governance. This adds to the recognition Medtronic received earlier this year through its continued inclusion in the FTSE4Good Index Series.

  • Thermo Fisher to Acquire BDX’s Advanced Bioprocessing Business
    Market Realist6 days ago

    Thermo Fisher to Acquire BDX’s Advanced Bioprocessing Business

    Thermo Fisher Scientific (TMO) announced on September 7, 2018, that the company will acquire Becton Dickinson’s (BDX) advanced bioprocessing business.

  • Thermo Fisher to Offer Complete Cannabis Testing Solutions
    Market Realist7 days ago

    Thermo Fisher to Offer Complete Cannabis Testing Solutions

    Thermo Fisher Scientific (TMO) announced on September 7, 2018, that the company offers end-to-end analytical solutions that comply with cannabis testing standards as defined by Health Canada.

  • How Thermo Fisher Fared in the Second Quarter
    Market Realist7 days ago

    How Thermo Fisher Fared in the Second Quarter

    Thermo Fisher Scientific (TMO) surpassed Wall Street analysts’ estimates for earnings per share (or EPS) and revenues during Q2 2018 and reported non-GAAP EPS of $2.75 on revenues of ~$6.1 billion during the quarter. The above chart compares the revenues since the first quarter of 2017.

  • How Thermo Fisher Scientific’s Valuation Looks in September
    Market Realist7 days ago

    How Thermo Fisher Scientific’s Valuation Looks in September

    Thermo Fisher Scientific (TMO) provides equipment, software, analytical instruments, reagents, consumables, and services. Thermo Fisher reported non-GAAP EPS of $2.75 on revenues of ~$6.1 billion, a 21.8% increase as compared to ~$5.0 billion during the second quarter of 2017. The below chart compares revenues and EPS for Thermo Fisher Scientific since the first quarter of 2017.

  • Medtronic (MDT) Initiates ONYX ONE- Clear Study on DAPT
    Zacks7 days ago

    Medtronic (MDT) Initiates ONYX ONE- Clear Study on DAPT

    Following a DAPT interruption at one month on patients with a next generation DES, the Onyx ONE Clear Study by Medtronic (MDT) investigates risk of cardiac death, heart attack and stent thrombosis.

  • Most Analysts Currently Call Boston Scientific a ‘Buy’
    Market Realist9 days ago

    Most Analysts Currently Call Boston Scientific a ‘Buy’

    Since January 2, Boston Scientific’s (BSX) share price has risen 41.4%. The company posted 6% YoY (year-over-year) organic revenue growth in the first half of 2018. The company is thus expected to witness revenue growth rates in the second half similar to those it witnessed in the first half.

  • Medtronic Announces One-Month DAPT Clinical Study in the U.S. and Japan with Resolute Onyx DES in High Bleeding Risk Patients
    GlobeNewswire9 days ago

    Medtronic Announces One-Month DAPT Clinical Study in the U.S. and Japan with Resolute Onyx DES in High Bleeding Risk Patients

    September 10, 2018 - Medtronic plc (MDT) today announced the start of the Onyx ONE Clear Study in the U.S. and Japan that will evaluate one-month dual antiplatelet therapy (DAPT) in high bleeding risk patients implanted with the Resolute Onyx(TM) Drug-Eluting Stent (DES) during percutaneous coronary intervention (PCI).1 The Onyx ONE Clear Study is one of the first studies in the U.S. and Japan designed to investigate safety - such as risk of cardiac death, heart attack and stent thrombosis - following DAPT interruption or discontinuation at one month with a next generation DES. "One-month DAPT duration after coronary stenting in high bleeding risk patients offers the potential to substantially enhance the safety of interventional procedures in these high-risk patients," said Gregg W. Stone, M.D., professor of medicine at Columbia University in New York, and program chair of the Onyx ONE Month DAPT Program.

  • What Teleflex’s Valuation Trend Indicates
    Market Realist9 days ago

    What Teleflex’s Valuation Trend Indicates

    From January 2–28, 2018, Teleflex (TFX) stock rose from $254.73 to $287.65, which was its high point so far in 2018. During the broader market turmoil in February, it dipped to a low of $242.67 on March 1. Then it made a steady recovery to $280 in June but has corrected again to its current level of $248.

  • Is It Too Late To Buy Medtronic plc (NYSE:MDT)?
    Simply Wall St.11 days ago

    Is It Too Late To Buy Medtronic plc (NYSE:MDT)?

    Medtronic plc (NYSE:MDT) saw a decent share price growth in the teens level on the NYSE over the last few months. As a large-cap stock with high coverage by analysts,Read More...

  • Analysts Still Bullish on Teleflex Stock
    Market Realist12 days ago

    Analysts Still Bullish on Teleflex Stock

    Teleflex’s (TFX) interest expenses increased from $19.89 million in the second quarter of 2017 to $26.65 million in the second quarter of 2018. Its income taxes, on the other hand, decreased from $12.1 million in the second quarter of 2017 to $9.58 million in the second quarter of 2018.

  • What Intuitive Surgical’s Valuation Trend Indicates
    Market Realist12 days ago

    What Intuitive Surgical’s Valuation Trend Indicates

    In September, of the 17 analysts covering Intuitive Surgical (ISRG), 11 have given its stock “buy” or higher ratings, five have given it “hold” ratings, and one has given it a “sell” rating.

  • Recent Product Approvals Bode Well for Intuitive Surgical
    Market Realist13 days ago

    Recent Product Approvals Bode Well for Intuitive Surgical

    This translated into a net income per share of $2.25 in the second quarter. Its net income per share was $2.01 in the second quarter of 2017. In July, Intuitive Surgical received FDA clearance for the marketing of its da Vinci EndoWrist Stapler, SureForm 60, which is a single-use stapling instrument with particular uses in bariatric procedures.

  • 3 Growth Stocks for Forward-Looking Investors
    Motley Fool13 days ago

    3 Growth Stocks for Forward-Looking Investors

    If you're a long-term investor, these growth stocks are for you.

  • What Analysts Expect for Abiomed
    Market Realist14 days ago

    What Analysts Expect for Abiomed

    How Do Abiomed’s Valuations Look in September? Wall Street analysts estimate Abiomed (ABMD) will report 29.9% growth in revenues to ~$771.0 million in 2019 as compared to $593.7 million in 2018. The earnings per share are expected to be $4.66 in 2019.

  • How Abiomed’s Revenue Trended in the First Quarter
    Market Realist14 days ago

    How Abiomed’s Revenue Trended in the First Quarter

    As discussed earlier, Abiomed (ABMD) reported revenues of $180.0 million in Q1 2019, a 36% increase as compared to revenues of ~$132.5 million in the first quarter of 2018.